Trial · NCT06160778
Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain
NCT06160778, Phase 3, Recruiting, University of Calgary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain. Trials, record NCT06160778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06160778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain
- NCT number
- NCT06160778
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 495 participants, estimated
- Lead sponsor
- University of Calgary
- Conditions
- Acute Pain, Abdomen, Acute, Abdominal Pain, Appendicitis, Emergencies, Child, Only
- Interventions
- Ketorolac Tromethamine, Morphine Sulfate, normal saline, Normal saline
- First posted
- 2023-12-07
- Last updated
- 2024-06-24
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain relief as measured on the verbal numerical rating scale | 60 minutes post drug administration | Between group mean differences in pain as measured on an 11-point verbal Numerical Rating Scale (0 is no pain and 10 is worst pain ever) |
| Secondary | Pain relief as measured on the verbal numerical rating scale | 30 minutes post drug administration | Between group mean differences in pain as measured on an 11-point verbal |
| Secondary | Pain relief as measured on the verbal numerical rating scale | 90 minutes post drug administration | Between group mean differences in pain as measured on an 11-point verbal |
| Secondary | Pain relief as measured on the verbal numerical rating scale | 120 minutes post drug administration | Between group mean differences in pain as measured on an 11-point verbal |
| Secondary | Pain relief as measured on the verbal numerical rating scale | 6 hours post drug administration | Between group mean differences in pain as measured on an 11-point verbal |
| Secondary | Pain relief as measured on the verbal numerical rating scale during the ultrasound diagnostic | up to 6 hours post drug administration | score from 0-10 on verbal numerical rating scale |
| Secondary | Proportion who achieve the minimal important difference for pain relief | 60 minutes post drug administration | Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction |
| Secondary | Proportion who achieve the minimal important difference for pain relief | 120 minutes post drug administration | Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction |
| Secondary | Change in baseline pain category | 30 minutes post drug administration | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe \>7) |
| Secondary | Change in baseline pain category | 60 minutes post drug administration | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe \>7) |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06160778
GET https://conductscience.org/api/trials/v1/NCT06160778/registered?page=2